Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

被引：0
|
作者：
Daniele Ouellet
Nastya Kassir
Joannellyn Chiu
Mohamad-Samer Mouksassi
Cathrine Leonowens
Donna Cox
Douglas J. DeMarini
Olivia Gardner
Wendy Crist
Kiran Patel
机构：
[1] GlaxoSmithKline,
[2] Janssen Research & Development,undefined
[3] Certara Strategic Consulting,undefined
[4] Inncelerex,undefined
[5] ,undefined
[6] Genentech,undefined
[7] Incyte Corporation,undefined
[8] Teva Pharmaceuticals,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 77卷
关键词：
Pharmacokinetics; NONMEM; Exposure–response; Melanoma; MEK inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：807 / 817
页数：10
相关论文
共 50 条
  • [21] Treatment of patients with advanced melanoma harboring the BRAF V600 mutation
    Polowinczak-Przybylek, Joanna
    Potemski, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (01): : 48 - 52
  • [22] Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
    Gao, Tianfu
    Liu, Jia
    Wu, Jing
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (12)
  • [23] The efficacy and safety of the combination of anti-BRAF agent and MEK inhibitor in advanced melanoma patients with BRAF V600 mutation: A meta-analysis.
    Xie, Changqing
    Mishriky, Basem Mourad Labib
    Chae, Phillip
    Atluri, Prashanti
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] COST-EFFECTIVENESS OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB IN THE TREATMENT OF BRAF V600 MUTATION-POSITIVE METASTATIC MELANOMA
    Cai, C.
    Yunusa, I
    Tarhini, A.
    VALUE IN HEALTH, 2022, 25 (07) : S300 - S300
  • [25] Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
    Nigel Fleeman
    Adrian Bagust
    Sophie Beale
    Angela Boland
    Rumona Dickson
    Kerry Dwan
    Marty Richardson
    Yenal Dundar
    Helen Davis
    Lindsay Banks
    PharmacoEconomics, 2015, 33 : 893 - 904
  • [26] Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Boland, Angela
    Dickson, Rumona
    Dwan, Kerry
    Richardson, Marty
    Dundar, Yenal
    Davis, Helen
    Banks, Lindsay
    PHARMACOECONOMICS, 2015, 33 (09) : 893 - 904
  • [27] Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation-Positive Melanoma: Patient Selection and Perspectives
    Dugan, Michelle M.
    Perez, Matthew C.
    Karapetyan, Lilit
    Zager, Jonathan S.
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 933 - 939
  • [28] Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
    Thomas E. Delea
    Jordan Amdahl
    Alice Wang
    Mayur M. Amonkar
    Marroon Thabane
    PharmacoEconomics, 2015, 33 : 367 - 380
  • [29] Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
    Delea, Thomas E.
    Amdahl, Jordan
    Wang, Alice
    Amonkar, Mayur M.
    Thabane, Marroon
    PHARMACOECONOMICS, 2015, 33 (04) : 367 - 380
  • [30] Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
    Igor Puzanov
    Journal of Translational Medicine, 13 (Suppl 1)
12345